GSK PLC (LSE/NYSE: GSK) has received regulatory approval from the National Medical Products Administration of China for Nucala (mepolizumab) as an add-on maintenance therapy for adults with eosinophilic chronic obstructive pulmonary disease (COPD) inadequately controlled on inhaled triple therapy. The greenlight marks a strategic respiratory expansion for GSK in the world’s largest COPD market and introduces China’s first approved monthly biologic targeting blood eosinophil counts starting at 150 cells/µL.

The approval is based on positive outcomes from the phase III METREX and MATINEE trials, where mepolizumab significantly reduced exacerbation frequency, including emergency department and hospital visits, among patients with type 2 inflammation. By penetrating China’s severe COPD segment, GSK is extending its type 2 inflammation franchise beyond asthma and nasal polyps into a high-burden, high-mortality indication where current standards of care leave millions inadequately controlled.

How does GSK’s Nucala approval reshape the biologic landscape for COPD in China?

The Nucala approval gives GSK first-mover advantage in biologics for eosinophilic COPD in China, a country that accounts for over 30% of global COPD-related deaths. With approximately 100 million diagnosed cases and 67% of uncontrolled patients exhibiting elevated eosinophil counts above 150 cells/µL, GSK has tapped into a high-prevalence niche where inhaled corticosteroids, long-acting beta agonists, and muscarinic antagonists often fall short.

Unlike prior COPD biologics that struggled with regulatory or commercial traction due to heterogeneity of response and cost-effectiveness concerns, Nucala’s positioning is tightly focused: it is being deployed in patients with a defined eosinophilic phenotype, supported by biomarker-stratified trial data and an urgent need to reduce exacerbation-driven hospitalisations. This alignment of biomarker-guided eligibility with payer and policy interest in reducing emergency admissions gives Nucala stronger clinical and economic justification than prior attempts in biologic COPD care.

Notably, the MATINEE trial showed a 21% reduction in moderate/severe exacerbations and a 35% relative reduction in exacerbations requiring emergency department visits or hospitalisation when compared to placebo. METREX further confirmed similar trends, cementing the case for using eosinophil count as a predictive biomarker to guide therapy escalation. This biomarker-led narrative is likely to appeal to China’s tiered public health insurance system, especially if pharmacoeconomic models demonstrate reduced acute care burden.

What execution risks does GSK face in converting regulatory approval into commercial traction?

While the regulatory milestone is significant, GSK must still navigate challenges in physician adoption, biomarker testing availability, payer acceptance, and patient access. COPD remains underdiagnosed and undertreated in many parts of China, particularly in secondary and rural healthcare settings. The infrastructure for routine blood eosinophil count testing, which is a prerequisite for identifying eligible patients, may not be uniformly available, especially outside top-tier urban hospitals.

Additionally, biologic pricing in China’s evolving reimbursement environment remains a risk. While Nucala is already marketed for asthma and nasal polyps in China, its expansion into COPD may trigger new scrutiny under the National Reimbursement Drug List (NRDL) negotiations, where discounts can exceed 60%. GSK will likely pursue inclusion in the NRDL to drive volume, but must be prepared to accept margin compression as part of the tradeoff.

A further complexity is the current lack of long-term real-world evidence in Chinese COPD populations. Although the global MATINEE and METREX trials included broad patient populations, local clinicians and payers may seek further post-marketing data before widespread adoption, especially given the historical scepticism around biologics in COPD where non-responders can drive up costs without proportional benefit.

How does Nucala’s profile compare to other late-stage or approved COPD biologics?

GSK’s Nucala is now positioned as the most clinically validated and regulatorily accepted eosinophilic COPD biologic in China. Other biologics, including Benralizumab from AstraZeneca and Dupilumab from Sanofi and Regeneron, have ongoing or past development programs in COPD, but none have yet secured approval in China for this indication. Benralizumab, an anti-IL-5 receptor alpha monoclonal antibody, has shown promising reduction in exacerbation rates in high-eosinophil subgroups but awaits further global approvals for COPD.

Dupilumab, targeting IL-4 and IL-13 pathways, is also under evaluation in type 2 high COPD populations. However, its broader mechanism and systemic immunomodulatory effects could present tolerability or economic tradeoffs in a high-prevalence market like China.

Nucala’s narrower mechanism, involving selective IL-5 inhibition, and monthly subcutaneous administration make it a pragmatic option, especially when paired with a biomarker-driven patient selection strategy. This simplicity could support adherence, cost forecasting, and long-term positioning as the default eosinophilic add-on in respiratory clinics.

What does this approval signal about GSK’s broader respiratory and China-focused strategy?

The Nucala COPD approval represents a continuation of GSK’s long-term bet on eosinophilic-driven respiratory diseases and builds on its legacy in asthma, where Nucala was one of the earliest anti-IL-5 drugs to gain regulatory traction globally. In China, GSK has already established an ecosystem of respiratory sales, biomarker education, and access strategies through its severe asthma and nasal polyps programs. Extending this platform into COPD not only leverages sunk investments but creates synergy across its biologic detailing infrastructure.

Strategically, this move also aligns with GSK’s wider pivot toward specialty and biologic therapies following divestments in consumer healthcare and reallocation of R&D capital into higher-margin segments. It also underscores GSK’s confidence in expanding its China prescription drug portfolio amid tightening domestic competition, rising local biologic capabilities, and regulatory reforms that reward value-based pricing.

The respiratory franchise remains one of GSK’s core earnings contributors, and defending it against biosimilar encroachment in asthma or pricing pressure in general inhalers will require moving up the value chain into complex diseases like COPD. Nucala’s use in eosinophilic COPD offers a beachhead in this effort.

What are the commercial implications for peers and domestic biopharma companies?

For multinational peers such as AstraZeneca and Sanofi, GSK’s early foothold in China’s eosinophilic COPD space sets a new benchmark for trial design, biomarker justification, and regulatory engagement. Future applications for Benralizumab or Dupilumab in COPD will likely be judged in the context of Nucala’s data and rollout strategy. If GSK can establish strong reimbursement, hospital listing, and physician demand within the first 18–24 months, it may lock in early-mover loyalty among key prescribers.

Domestic Chinese biopharma firms may also find this a signal to accelerate development of IL-5 pathway biosimilars or alternative inflammation-targeting biologics. However, replicating GSK’s dual-trial strategy and regulatory acceptance in biomarker-defined COPD may prove difficult without a significant R&D track record or global regulatory collaboration.

The broader implication is that China’s biologics market is expanding not just in oncology or immunology, but in respiratory medicine, where specialty pathways and precision medicine have lagged. Nucala’s approval could be a leading indicator for the viability of biomarker-aligned biologics in other high-burden chronic diseases within the country.

  China NMPA, chronic obstructive pulmonary disease, GSK plc, mepolizumab, METREX trial, Nucala